130 related articles for article (PubMed ID: 30552114)
1. Cytochrome P450 1A1 opens up to new substrates.
Munro AW
J Biol Chem; 2018 Dec; 293(50):19211-19212. PubMed ID: 30552114
[TBL] [Abstract][Full Text] [Related]
2. Structures of human cytochrome P450 1A1 with bergamottin and erlotinib reveal active-site modifications for binding of diverse ligands.
Bart AG; Scott EE
J Biol Chem; 2018 Dec; 293(50):19201-19210. PubMed ID: 30254074
[TBL] [Abstract][Full Text] [Related]
3. Human Cytochrome P450 1A1 Adapts Active Site for Atypical Nonplanar Substrate.
Bart AG; Takahashi RH; Wang X; Scott EE
Drug Metab Dispos; 2020 Feb; 48(2):86-92. PubMed ID: 31757797
[TBL] [Abstract][Full Text] [Related]
4. Human cytochrome P450 1A1 structure and utility in understanding drug and xenobiotic metabolism.
Walsh AA; Szklarz GD; Scott EE
J Biol Chem; 2013 May; 288(18):12932-43. PubMed ID: 23508959
[TBL] [Abstract][Full Text] [Related]
5. Molecular modeling of cytochrome P450 1A1: enzyme-substrate interactions and substrate binding affinities.
Szklarz GD; Paulsen MD
J Biomol Struct Dyn; 2002 Oct; 20(2):155-62. PubMed ID: 12354067
[TBL] [Abstract][Full Text] [Related]
6. 7-Ethynylcoumarins: selective inhibitors of human cytochrome P450s 1A1 and 1A2.
Liu J; Nguyen TT; Dupart PS; Sridhar J; Zhang X; Zhu N; Stevens CL; Foroozesh M
Chem Res Toxicol; 2012 May; 25(5):1047-57. PubMed ID: 22443586
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of human and rat CYP1A1 enzyme by grapefruit juice compounds.
Santes-Palacios R; Romo-Mancillas A; Camacho-Carranza R; Espinosa-Aguirre JJ
Toxicol Lett; 2016 Sep; 258():267-275. PubMed ID: 27444380
[TBL] [Abstract][Full Text] [Related]
8. Ethynylflavones, highly potent, and selective inhibitors of cytochrome P450 1A1.
Goyal N; Liu J; Lovings L; Dupart P; Taylor S; Bellow S; Mensah L; McClain E; Dotson B; Sridhar J; Zhang X; Zhao M; Foroozesh M
Chem Res Toxicol; 2014 Aug; 27(8):1431-9. PubMed ID: 25033111
[TBL] [Abstract][Full Text] [Related]
9. Characterization of differences in substrate specificity among CYP1A1, CYP1A2 and CYP1B1: an integrated approach employing molecular docking and molecular dynamics simulations.
Kesharwani SS; Nandekar PP; Pragyan P; Rathod V; Sangamwar AT
J Mol Recognit; 2016 Aug; 29(8):370-90. PubMed ID: 26916064
[TBL] [Abstract][Full Text] [Related]
10. Exploring CYP1A1 as anticancer target: homology modeling and in silico inhibitor design.
Sangamwar AT; Labhsetwar LB; Kuberkar SV
J Mol Model; 2008 Nov; 14(11):1101-9. PubMed ID: 18665399
[TBL] [Abstract][Full Text] [Related]
11. Ortho-Methylarylamines as Time-Dependent Inhibitors of Cytochrome P450 1A1 Enzyme.
Sridhar J; Liu J; Komati R; Schroeder R; Jiang Q; Tram P; Riley K; Foroozesh M
Drug Metab Lett; 2017; 10(4):270-277. PubMed ID: 28000546
[TBL] [Abstract][Full Text] [Related]
12. Theoretical investigation of differences in nitroreduction of aristolochic acid I by cytochromes P450 1A1, 1A2 and 1B1.
Jerabek P; Martinek V; Stiborova M
Neuro Endocrinol Lett; 2012; 33 Suppl 3():25-32. PubMed ID: 23353840
[TBL] [Abstract][Full Text] [Related]
13. Preferred binding orientations of phenacetin in CYP1A1 and CYP1A2 are associated with isoform-selective metabolism.
Huang Q; Deshmukh RS; Ericksen SS; Tu Y; Szklarz GD
Drug Metab Dispos; 2012 Dec; 40(12):2324-31. PubMed ID: 22949628
[TBL] [Abstract][Full Text] [Related]
14. Regiospecificity of human cytochrome P450 1A1-mediated oxidations: the role of steric effects.
Ericksen SS; Szklarz GD
J Biomol Struct Dyn; 2005 Dec; 23(3):243-56. PubMed ID: 16218752
[TBL] [Abstract][Full Text] [Related]
15. Structural Insights into the Interaction of Cytochrome P450 3A4 with Suicide Substrates: Mibefradil, Azamulin and 6',7'-Dihydroxybergamottin.
Sevrioukova IF
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31480231
[TBL] [Abstract][Full Text] [Related]
16. The Grapefruit Effect: Interaction between Cytochrome P450 and Coumarin Food Components, Bergamottin, Fraxidin and Osthole. X-ray Crystal Structure and DFT Studies.
Rossi M; Aktar S; Davis M; Hefter Feuss E; Roman-Holba S; Wen K; Gahn C; Caruso F
Molecules; 2020 Jul; 25(14):. PubMed ID: 32664320
[TBL] [Abstract][Full Text] [Related]
17. Spectral modification and catalytic inhibition of human cytochromes P450 1A1, 1A2, 1B1, 2A6, and 2A13 by four chemopreventive organoselenium compounds.
Shimada T; Murayama N; Tanaka K; Takenaka S; Guengerich FP; Yamazaki H; Komori M
Chem Res Toxicol; 2011 Aug; 24(8):1327-37. PubMed ID: 21732699
[TBL] [Abstract][Full Text] [Related]
18. Understanding the mechanism of cytochrome P450 3A4: recent advances and remaining problems.
Sevrioukova IF; Poulos TL
Dalton Trans; 2013 Mar; 42(9):3116-26. PubMed ID: 23018626
[TBL] [Abstract][Full Text] [Related]
19. Application of molecular modeling for prediction of substrate specificity in cytochrome P450 1A2 mutants.
Tu Y; Deshmukh R; Sivaneri M; Szklarz GD
Drug Metab Dispos; 2008 Nov; 36(11):2371-80. PubMed ID: 18703643
[TBL] [Abstract][Full Text] [Related]
20. Docking and QSAR comparative studies of polycyclic aromatic hydrocarbons and other procarcinogen interactions with cytochromes P450 1A1 and 1B1.
Gonzalez J; Marchand-Geneste N; Giraudel JL; Shimada T
SAR QSAR Environ Res; 2012 Jan; 23(1-2):87-109. PubMed ID: 22150106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
